{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:35Z","timestamp":1792078955623,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["105012"],"award-info":[{"award-number":["105012"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ahj.2021.06.010","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T03:21:37Z","timestamp":1624591297000},"page":"101-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial)"],"prefix":"10.1016","volume":"240","author":[{"given":"Rajiv","family":"Ananthakrishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sau L","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta C","family":"Sallustio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Binda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arduino A","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Semsarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-4265","authenticated-orcid":false,"given":"Joseph B","family":"Selvanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.06.010_bib0001","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0002","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0008-6363(99)00213-8","article-title":"Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy","volume":"44","author":"Redwood","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2021.06.010_bib0004","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","article-title":"Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion","volume":"19","author":"Ashrafian","year":"2003","journal-title":"Trends Genet"},{"key":"10.1016\/j.ahj.2021.06.010_bib0005","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/eurjhf\/hfr135","article-title":"Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction","volume":"13","author":"Timmer","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2021.06.010_bib0006","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","article-title":"Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy","volume":"41","author":"Crilley","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0007","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.1996.03540030033028","article-title":"Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles","volume":"276","author":"Maron","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.06.010_bib0008","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/hrt.78.2.182","article-title":"Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy","volume":"78","author":"Cox","year":"1997","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2021.06.010_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0006-2952(96)00204-3","article-title":"Inhibition of carnitine palmitoyltransferase-1in rat heart and liver by perhexiline and amiodarone","volume":"52","author":"Kennedy","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jchf.2014.09.009","article-title":"Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy","volume":"3","author":"Beadle","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2021.06.010_bib0011","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/01.CIR.81.4.1260","article-title":"Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent","volume":"81","author":"Cole","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.010_bib0012","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1161\/CIRCULATIONAHA.105.551457","article-title":"Metabolic modulation with Perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment","volume":"112","author":"Lee","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.010_bib0013","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator Perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.010_bib0014","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1039\/C4MB00594E","article-title":"Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy","volume":"11","author":"Gehmlich","year":"2015","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.ahj.2021.06.010_bib0015","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2021.06.010_bib0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.2002.01618.x","article-title":"Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose","volume":"54","author":"Sallustio","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0017","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2004.09.020","article-title":"Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model","volume":"44","author":"Amado","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCIMAGING.109.860148","article-title":"Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease","volume":"3","author":"Karamitsos","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2021.06.010_bib0019","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc0402.102975","article-title":"Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the american heart association","volume":"105","author":"Cerqueira","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.ahj.2021.06.010_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jmri.20504","article-title":"Effect of Gd-DTPA-BMA on blood and myocardial T1 at 1.5T and 3T in humans","volume":"23","author":"Sharma","year":"2006","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ahj.2021.06.010_bib0021","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/RLI.0b013e31824f54cb","article-title":"Magnetic resonance perfusion of the myocardium: semiquantitative and quantitative evaluation in comparison with coronary angiography and fractional flow reserve","volume":"47","author":"Huber","year":"2012","journal-title":"Invest Radiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamacardio.2018.4953","article-title":"Nonobstructive hypertrophic cardiomyopathy-the high-hanging fruit","volume":"4","author":"Day","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0023","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2021.06.010_bib0024","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial substrate metabolism in the normal and failing heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ahj.2021.06.010_bib0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yjmcc.2012.12.014","article-title":"Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome","volume":"55","author":"Yin","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0027","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1161\/CIRCULATIONAHA.110.981464","article-title":"Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation","volume":"122","author":"Horowitz","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.010_bib0028","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1023\/A:1007768716934","article-title":"Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart","volume":"12","author":"Kennedy","year":"1998","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ahj.2021.06.010_bib0029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2021.06.010_bib0031","article-title":"Progression of myocardial fibrosis in hypertrophic cardiomyopathy: a cardiac magnetic resonance study","author":"Habib","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2021.06.010_bib0032","first-page":"419","article-title":"Perhexiline maleate-induced hepatitis","volume":"17","author":"Paliard","year":"1978","journal-title":"Digestion"},{"key":"10.1016\/j.ahj.2021.06.010_bib0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02089960","article-title":"Pharmacokinetics of Perhexiline maleate in anginal patients with and without peripheral neuropathy","volume":"14","author":"Singlas","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0034","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00008571-200310000-00006","article-title":"Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status","volume":"13","author":"Barclay","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ahj.2021.06.010_bib0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0167-5273(86)90146-4","article-title":"Perhexiline maleate treatment for severe angina pectoris\u2013correlations with pharmacokinetics","volume":"13","author":"Horowitz","year":"1986","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0036","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2125.2003.02003.x","article-title":"Concentration-time profile for Perhexiline and hydroxyPerhexiline in patients at steady state","volume":"57","author":"Jones","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0037","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1527-3466.2007.00006.x","article-title":"Perhexiline","volume":"25","author":"Ashrafian","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.ahj.2021.06.010_bib0038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/FTD.0000000000000237","article-title":"Can perhexiline be utilized without long-term toxicity? a clinical practice audit","volume":"38","author":"Phuong","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ahj.2021.06.010_bib0039","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jacc.2012.01.055","article-title":"Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 tesla","volume":"59","author":"Arnold","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0040","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ehjci\/jey220","article-title":"Assessment of myocardial oxygenation, strain, and diastology in MYBPC3-related hypertrophic cardiomyopathy: a cardiovascular magnetic resonance and echocardiography study","volume":"20","author":"Grover","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2021.06.010_bib0041","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacc.2012.12.024","article-title":"Blunted myocardial oxygenation response during vasodilator stress in patients with hypertrophic cardiomyopathy","volume":"61","author":"Karamitsos","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.010_bib0042","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jcmg.2018.12.014","article-title":"Prognostic utility of oxygen-sensitive cardiac magnetic resonance imaging in diabetic and nondiabetic chronic kidney disease patients with no known coronary artery disease","volume":"12","author":"Shah","year":"2019","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:56:40Z","timestamp":1778644600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":42,"alternative-id":["S0002870321001666"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.06.010","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}